This session contains links to financial disclosure, information meeting, press conference, and other presentation materials and movie files.
Latest Presentation Materials
First Quarter Financial Results for Fiscal Year Ending March 31, 2025 (Live Video Streaming)
| Date / Time |
Friday, August 2, 2024 15:00 - 16:00 (JST) |
|---|---|
| Location |
Corporate Headquarters, 精东影业., Tokyo, JAPAN |
New Clinical Data of LEQEMBI庐 (lecanemab-irmb) Presented at The Alzheimer鈥檚 Association International Conference (AAIC) 2024
| Date / Time |
July 30, 2024 (EDT) |
|---|
| 鈻�&苍产蝉辫;Perspectives Session:
Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer’s Disease? |
|---|
| Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing? |
| How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing? |
| Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model Supports Continued Lecanemab Treatment With Maintenance Dosing For Alzheimer’s Disease |
| Is there Evidence for a Continued Benefit for Long-Term Lecanemab Treatment?
A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data |
| 鈻�&苍产蝉辫;Featured Research Session:
Beyond Amyloid Removal with Lecanemab Treatment: Update on Long-Term Imaging and Fluid Biomarkers |
|---|
| Amyloid Plaque Reduction as a Biomarker of Efficacy: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model |
| Lecanemab Slows Tau PET Accumulation |
| “Paradoxical” Cerebral Volume Changes in Anti-Amyloid Immunotherapy Trials |
| Long-Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma |
銆赌
Other Presentation Materials
Past Other Presentation Materials
The files are in Adobe PDF Format. To view them you will need to download the Adobe Reader.
Adobe Reader, the Acrobat logo are trademarks of Adobe Systems Incorporated.